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The inﬂammasome is a caspase-1-activating complex that is implicated in a growing number of acute
and chronic pathologies. Interest has increased in identifying small molecular inhibitors of inﬂamma-
some signaling because of its role in clinically relevant diseases. It was recently reported that the protein
tyrosine kinase, Syk, regulates pathogen-induced inﬂammasome signaling by phosphorylating a mo-
lecular switch on the adapter protein ASC. However, several aspects of the role of Syk in inﬂammasome
signaling and the effects of its inhibition remain unclear. The aim of the present study is to explore in
detail the effects of the oxindole Syk inhibitor OXSI-2 on various aspects of nigericin-induced inﬂam-
masome signaling. Our results indicate that OXSI-2 inhibits inﬂammasome assembly, caspase-1 activa-
tion, IL-1b processing and release, mitochondrial ROS generation, and pyroptotic cell death. Using a novel
live cell potassium sensor we show that Syk inhibition with OXSI-2 has no effect on potassium efﬂux
kinetics and that blockade of potassium efﬂux with extracellular potassium alters Syk phosphorylation.
The effects of OXSI-2 identiﬁed in this study provide context for the role of Syk in inﬂammasome
signaling and demonstrate its importance in oxidative signaling upstream of inﬂammasome activation
and downstream of ion ﬂux.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The innate immune system rapidly responds to a variety of
endogenous and exogenous danger signaling by assembling a
multi-protein complex called the inﬂammasome [1]. The outcome
of inﬂammasome assembly is activation of the enzyme caspase-1,
leading to the processing and release of interleukin-1b (IL-1b)
and other pro-inﬂammatory cytokines, as well as a pro-
inﬂammatory cell death called pyroptosis [2,3].
Recent evidence highlights the importance of post-translational-containing 3; IL-1b, inter-
itochondrial reactive oxygen
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Inc. This is an open access article usignaling in licensing the inﬂammasome for assembly [4]. This
rapid licensing is in contrast to canonical models for inﬂammasome
activation that depend on a TLR4-dependent priming period fol-
lowed by a rapid stimulation period [5,6]. Rapid licensing is bio-
logically rational as post-translational signaling occurs more
quickly than de novo transcription and translation of effector pro-
teins, and enables a more rapid innate immune response to danger
signals. A role for post-translational modiﬁcations in regulation of
the inﬂammasome is further supported by the discovery of a
tyrosine phosphorylation site on the inﬂammasome adapter pro-
tein Apoptosis-associated Speck-like protein containing a Caspase
recruitment domain (ASC) that acts as a molecular switch con-
trolling inﬂammasome assembly [7,8]. Phosphorylation of ASC is
mediated in large part by spleen tyrosine kinase (Syk), a protein
tyrosine kinase that is essential for inﬂammasome-mediated re-
sponses to fungi, mycobacteria and malarial hemozoin [9e11].
However, beyond the interaction between Syk and ASC, there is
little understanding of the context of Syk in the inﬂammasomender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Interest has grown in identifying pharmacological inhibitors of
the inﬂammasome due to the clinical relevance of inﬂammation
[14]. Here, we focus on the Syk inhibitor OXSI-2 [2,3-dihydro-3-[(1-
methyl-1H-indol-3-yl)methylene]-2-oxo-1H-indole-5-
sulfonamide] because the adenine-mimetic oxindole backbone is
highly ﬂexible for chemical modiﬁcation and has been useful for
developing other small molecule inhibitors, including bloodebrain
barrier-penetrating inhibitors [15e18]. OXSI-2 was discovered in a
screen for bioavailable, cell-permeable Syk inhibitors and was
identiﬁed as the most effective (EC50 ¼ 313 nM; IC50 ¼ 14 nM) in
cell-based assays among those identiﬁed [18]. Indeed, OXSI-2 is
also marketed under the explicit name “Syk Inhibitor” and was
included in the initial screen identifying a role of Syk in ASC
phosphorylation [7].
Our results indicate that OXSI-2 blocks inﬂammasome assembly
in response to the bacterial pore-forming toxin nigericin and,
accordingly, caspase-1 activation, IL-1b processing and release and
pyroptotic cell death. Further, OXSI-2 treatment potently sup-
presses mitochondrial reactive oxygen species (mROS) generation.
Utilizing a novel live cell potassium sensor we also show that the
effects of OXSI-2 treatment are downstream of nigericin-induced
potassium efﬂux and that Syk phosphorylation is affected by po-
tassium blockade. These results provide support for an early role for
Syk in the inﬂammasome signaling pathway, downstream of ion
ﬂux and upstream of oxidative signaling leading to inﬂammasome
assembly, pro-inﬂammatory signaling and pyroptosis.
2. Materials and methods
2.1. Reagents
LPS (from Escherichia coli O111:B4) was purchased from Sigma
Aldrich (St. Louis, MO, USA). Nigericin was purchased from Inviv-
ogen (San Diego, CA, USA) and Cayman (Ann Arbor, MI, USA). OXSI-
2 was purchased from Cayman. KS6 intracellular potassium sensor
was developed in-house (Center for Biosignatures Discovery
Automation, The Biodesign Institute, Arizona State University,
Tempe, AZ, USA) [19]. For complete list of reagents see Supple-
mental materials.
2.2. Cell culture
The mouse monocyte/macrophage cell line J774A.1 (ATCC TIB-
67™, Manassas, VA, USA) was grown in DMEM supplemented with
10% FBS, 100 m/mL Penicillin G and 100 mg/mL Streptomycin Sulfate
(all from Gibco, Grand Island, NY, USA). Tissue culture ﬂasks were
passaged every 3e4 days by scraping and cells were counted for
density and viability with a Countess® Automated Cell Counter (Life
Technologies) using the Trypan Blue dye exclusion assay.
2.3. Live cell potassium and mROS imaging
For imaging, cells were seeded in an 8-chamber m-Slide (Ibidi,
Verona, WI, USA) at a density of 1e2  105 per well in 200 mL of
complete DMEM. The following day cells were primed for 4 h with
1 mg/mL LPS. Inhibitors were added for the last 15 min of priming.
Cells were stimulated with 20 mM nigericin after an initial baseline
was taken. Cells were imaged on a Nikon Ti microscope equipped
with a C2si confocal scanner (Nikon Instruments, Melville, NY, USA)
and a Tokai Hit stage-top incubator (Tokai Hit Co., Shizuoka, Japan).
Potassium imaging was performed as previously described
[19,20]. Brieﬂy, KS6 was diluted 1:1 with 10% w/v Pluronic F127 and
added to priming cells at 1:100 dilution. Final concentration of KS6
applied to cells was 5 mM. KS6 was excited at 561 nm and emissionwas collected in the TRITC channel.
For mROS imaging, MitoSOXwas added 15min after stimulation
at a ﬁnal concentration of 5 mM, concurrently with 10 mg/mL
Hoechst 33342 (Life Technologies) and incubated for an additional
15 min prior to imaging.
2.4. Caspase-1 FLICA assay
J774A.1 were seeded and primed as described for live cell im-
aging. During the last hour of priming cells were loaded with
1  FAM-YVAD-FMK (Caspase-1 FLICA) and 10 mg/mL Hoechst
33342 in complete medium. Additional inhibitors were added
during the last 15e20 min of priming. Cells were stimulated with
20 mMnigericin for 30 min, washed 2x with warm DMEM and ﬁxed
in 2% formaldehyde for 10 min. Cells were washed 1x with PBS and
submerged in 200 mL mounting medium (90% glycerol with 10X
PBS and 0.1% NaN3). Samples were imaged by laser-scanning
confocal microscopy as a series of 0.5 mm z-stacks. Stacks were
prepared as maximum intensity projections using ImageJ/FIJI
(v1.49f, http://www.ﬁji.sc).
2.5. Lactate dehydrogenase release assay
Cells were seeded in a 96-well tissue culture-treated plate at a
concentration of 105 cells/well. The following day the mediumwas
exchanged for 100 mL of either freshmedium ormedium containing
1 mg/mL LPS and incubation was continued for 4 h. Inhibitors were
added during the third hour of incubation. For stimulation, the
complete medium of each well was exchanged for 100 mL of either
fresh medium, medium containing 1% Triton X-100 as a maximum
release control, or the indicated drugs and/or inhibitors and
returned to the incubator for 1 h. Fifty mL of supernatant was
sampled for each well. Released lactate dehydrogenase was
measured using the CytoTox 96® Non-Radioactive Cytotoxicity
Assay according to manufacturer's instructions. The developed
assay was measured for absorbance at 492 nm on a Biotek Synergy
H4 multi-mode plate reader.
2.6. Syk immunoprecipitation
Brieﬂy, supernatants were collected from stimulated cell cul-
tures, then combined with cell lysates. The samples were centri-
fuged and protein content of the supernatant was quantiﬁed by
BCA assay. For immunoprecipitation, 1% BSA was added to each
protein sample and 40 mL of magnetic beads containing Syk capture
antibody were added. Samples were rotated overnight at 4 C. Then
the beads were washed 3x with cold RIPA by pull-down using a
magnetic bead stand and protein was collected by heating the
beads in denaturing Laemmli at 95 C for 10 min. See Supplemental
material for detailed protocol.
2.7. Immunoblotting
For non-immunoprecipitated protein collection, after stimula-
tion, supernatants were collected from cells and concentrated with
10 mL/mL StrataClean Resin. Cell lysates were collected by directly
adding 100 mL 1  hot denaturing Laemmli buffer to each well.
Proteins were run on 4e12% Mini-PROTEAN TGX gel then
transferred to 0.2 mm pore nitrocellulose membranes. Membranes
were probed independently with rabbit polyclonal against caspase-
1 p10, or goat polyclonal against IL-1b. For immunoprecipitation
experiments, membranes were multiplexed with mouse polyclonal
against p-Tyr to detect phospho-Syk in Syk-enriched IP eluates and
rabbit polyclonal against Syk to detect total Syk. Membranes were
incubated with appropriate secondary antibodies then imaged
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2.8. ELISA
Cells were seeded in 96-well plates at a concentration of
105 cells/well and incubated overnight. Cells were primed for 4 h
with 1 mg/mL LPS and subsequently stimulated for 60 min with
20 mM nigericin in 100 mL medium. Where indicated, inhibitors
were added 15e20 min prior to nigericin stimulation. Supernatants
were collected (100 mL per condition) and released IL-1b was
evaluated with ELISA using the R&D Systems DuoSet kit according
to the manufacturer's protocol. Developed plates were read on a
Biotek Synergy H4 mutli-mode plate reader.
2.9. Statistical analysis
Data were analyzed in GraphPad Prism version 6.05 (GraphPad,
La Jolla, CA, USA) using one-way ANOVAwith a Tukey's post-hoc or
Fischer's LSD comparison. Results were considered signiﬁcant if
p < 0.05.
3. Results
3.1. OXSI-2 blocks nigericin-induced inﬂammasome assembly
We ﬁrst explored the effect of Syk inhibition with OXSI-2 on
nigericin-induced NLRP3 inﬂammasome assembly [21]. Activated
caspase-1 can be ﬂuorescently tagged at the explicit site of acti-
vation (i.e., in the inﬂammasome itself) by pre-exposure to
Caspase-1 FLICA, a FAM-conjugated irreversible inhibitor for
caspase-1 containing the YVAD caspase-1 recognition sequence
[22]. Confocal imaging showed that LPS-primed, nigericin-treatedFig. 1. Syk activity is required for nigericin-induced inﬂammasome assembly. J774A.1 m
and stimulated with 20 mM nigericin for 30 min. Where indicated, cells were treated with 13
perinuclear caspase-1 specks classical for inﬂammasome assembly. Bar graph indicates mea
one-way ANOVA with Tukey's post-hoc comparison. Blue ﬂuorescence is Hoechst 33342 anJ774A.1 assemble the inﬂammasome as indicated by single, peri-
nuclear specks of FLICA-labeled caspase-1 (Fig. 1). As expected,
treatment with 130 mM extracelluar KCl to inhibit Kþ efﬂux, in-
hibits the assembly of the inﬂammasome. Importantly, OXSI-2 re-
sults in signiﬁcant suppression of caspase-1 specks.3.2. OXSI-2 suppresses pro-inﬂammatory protein processing, mROS
generation and pyroptotic cell death
Immunoblot analysis reveals a robust suppression of caspase-1
and IL-1b processing and release by both Syk inhibition and
extracellular potassium blockade as indicated by a reduction in
caspase-1 p10 and IL-1b p17 fragments in concentrated superna-
tants of stimulated J774A.1 cells (Fig. 2a). In agreement with the
immunoblot results, quantitative detection of processed and
released IL-1b by ELISA shows robust inhibition upon treatment
with extracellular KCl and OXSI-2 (Fig. 2b).
Mitochondrial destabilization and oxidative signaling have been
implicated in triggering inﬂammasome assembly [20,23e25].
Mitochondrial ROS generation was visualized by live cell imaging
with the reactive oxygen probe MitoSOX (Fig. 2c). MitoSOX oxida-
tion was suppressed by treatment with extracellular KCl or OXSI-2
demonstrating that this process is dependent on both potassium
efﬂux and Syk activity.
Inﬂammasome assembly can result in pro-inﬂammatory cell
death by caspase-1-dependent pyroptosis [3]. Pyroptosis was
measured by release of lactate dehydrogenase into the medium.
Pyroptosis in J774A.1 requires both LPS priming and nigericin
stimulation and, importantly, was blocked by both extracellular KCl
and treatment with OXSI-2 (Fig. 2d).ouse macrophage cells were left untreated, primed for 4 h with 1 mg/mL LPS or primed
0 mM KCl or 2 mM OXSI-2 for 15e20 min prior to addition of nigericin. Arrows indicate
n and standard error of at least 3 ﬁelds from 2 independent experiments evaluated by
d green ﬂuorescence is caspase-1 FLICA. Scale bar represents 25 mm.
Fig. 2. Syk and potassium efﬂux are critical for inﬂammasome signaling and pyroptosis. (a) Immunoblot analysis of caspase-1 and IL-1b in the cell lysates and concentrated
supernatants. Where indicated, cells were treated with 1 mg/mL LPS, inhibited with 130 mM KCl or 2 mM OXSI-2 and stimulated with nigericin. Caspase-1 p45 and p10 and proIL-1b
and bioactive IL-1b are indicated by arrows (b) Quantitative ELISA of IL-1b in the supernatants of cells treated as in (a). Bars represent mean and standard error. Statistics were
calculated by one-way ANOVA with Tukey's post-hoc comparison. Results represent at least two independent experiments. (c) J774A.1 cells were untreated, primed with LPS, or
primed and then treated with 20 mM nigericin. Where indicated, cells were treated with 130 mM KCl or 2 mM OXSI-2 for 15e20 min prior to nigericin addition. Cells were stained
with 5 mM MitoSOX and then imaged by confocal microscopy. Results are representative of two independent experiments. Scale bar represents 25 mm. (d) J774A.1 cells were
untreated, primed with LPS, or primed and then treated with 20 mM nigericin. Where indicated, cells were treated with 130 mM KCl or 2 mM OXSI-2. Released LDH was measured in
cell-free supernatants. Bars represent mean and standard error of two independent experiments evaluated by one-way ANOVA with Tukey's post-hoc comparison.
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induced potassium efﬂux
Because both extracellular potassium blockade and OXSI-2
treatment inhibit inﬂammasome assembly, we sought to deter-
mine whether OXSI-2 treatment would modulate nigericin-
induced potassium efﬂux. We recently developed a novel intra-
cellular potassium sensor, KS6, for real-time imaging of potassium
dynamics in live cells and have applied it to inﬂammasome
signaling [19,20]. KS6 responses revealed no difference in the ki-
netics of potassium efﬂux induced by nigericin treatment in LPS-
primed cells with or without OXSI-2 treatment (Fig. 3a).
Quantitative, multiplexed immunoblots of immunoprecipitated
Syk, probed for total Syk and phospho-tyrosine residues, indicated
that blockade of potassium efﬂux with extracellular KCl results in a
signiﬁcant alteration of phospho-Syk levels in LPS-primed, niger-
icin-stimulated cells (Fig. 3b). In agreement with other reports, a
slow loss of phospho-Syk signal after the initial stimulus was
observed [7]. However, addition of extracellular KCl resulted in a
rapid and dramatic dephosphorylation of Syk following stimula-
tion. Control experiments were performed on unprimed cells to
determine whether simply the addition of KCl could drive this Syk
dephosphorylation (Fig. 3c). There was no observable difference
between treatment with nigericin or KCl alone, or the combination
of nigericin and KCl. These data suggest a requirement for TLR4-
dependent priming with LPS in order to produce conditionswherein Syk phosphorylation is sensitive to potassium efﬂux.
Taken together, these results indicate that Syk phosphorylation is
downstream of potassium efﬂux in inﬂammasome signaling.4. Discussion
How inﬂammasome assembly is initiated by structurally and
functionally diverse stimuli is not well understood and presents a
challenge for intervening with inﬂammasome signaling [1,14,26].
Speciﬁc upstream proteins are attractive for pharmacologic inhi-
bition and a number of new targets including Syk have been
recently identiﬁed [7,8,27e31].
Here we investigated the functional effects of pharmacologic
Syk inhibition on canonical, nigericin-induced inﬂammasome
signaling. We report that OXSI-2 treatment potently inhibits
inﬂammasome complex assembly, caspase-1 activation and IL-1b
processing and release in the J774A.1 mouse macrophage cell line.
To further elucidate the mechanism by which Syk regulates the
inﬂammasome, we explored effects of OXSI-2 treatment on the
generation of mitochondrial ROS, since oxidative signaling has been
implicated in triggering NLRP3 inﬂammasome assembly and
pyroptosis [32,33]. Use of the mROS probe MitoSOX revealed that
activated cells displayed substantial mROS production. This
response was inhibited by both KCl blockade and OXSI-2 treatment,
placing potassium and Syk activity upstream of mitochondrial
dysfunction. These results contrast with the work of Hara et al. who
Fig. 3. Syk activity is dispensable for, and downstream of, nigericin-induced potassium efﬂux. (a) LPS-primed J774A.1 macrophages were loaded with KS6 potassium sensor and
stimulated with 20 mM nigericin before continuous imaging. Where indicated, cells were treated with 2 mM OXSI-2 for 15e20 min prior to nigericin treatment. Red box indicates
selected region expanded in kymograph panels. Traces indicated mean and standard deviation of KS6 signal change for 5 cells in a representative ﬁeld from each condition. Scale bar
represents 25 mm. Results are representative of at least two independent experiments. (b) J774A.1 mouse macrophages were left untreated or primed for 4 h with 1 mg/mL LPS
before treatment with 20 mMnigericin for the indicated time. 130 mM KCl was added to the mediumwhere indicated. Immunoprecipitation was performed on combined lysates and
supernatants. Multiplexed infrared immunoblots were performed with total Syk and phospho-tyrosine (pY) antibodies. The ratios of pY signal to total Syk were calculated and
normalized to untreated controls (bar graph). (c) J774A.1 cells were left untreated or directly treated with 20 mM nigericin, 130 mM KCl or a combination of both for 15 min and
processed as described in (b). Bar graphs indicate mean of two independent experiments and error bars indicate standard deviations. P-values were calculated using one-way
ANOVA with a Fischer's LSD multiple comparison test. IP control indicates total Syk-conjugated Protein A Dynabeads left unexposed to collected protein.
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induced MitoSOX oxidation [7]. This is likely the result of meth-
odological differences. In the Hara et al. study, macrophages were
incubated in nigericin and MitoSOX simultaneously for 20 min. LPS
priming induces TLR4-dependent mROS generation and thus
MitoSOX ﬂuorescence will increase as soon as it is added to cells
[34]. In the current study, MitoSOX was added after a period of
nigericin treatment resulting in a lower background signal from the
LPS-induced mROS generation alone. We recommend this
approach in order to avoid limitations of the MitoSOX sensor.
A terminal outcome of inﬂammasome assembly is a caspase-1-
dependent, pro-inﬂammatory cell death called pyroptosis [2,3].
Despite recent interest in the role of Syk in inﬂammasome
signaling, it remained unclear whether Syk was involved in
signaling events resulting in pyroptotic cell death [13]. Here, we
demonstrate that treatment with OXSI-2 blocks pyroptosis andprevents the release of lactate dehydrogenase into the supernatant,
a conventional read-out of pyroptosis [35].
Potassium ion ﬂux is a driving mechanism in inﬂammasome
signaling [20,36,37]. Here, we show that Syk inhibitionwith OXSI-2
blocks the outcomes of nigericin-induced inﬂammasome assembly,
but does not inhibit potassium efﬂux as measured in real-time by a
live cell probe [19,20]. We explored this further by blocking po-
tassium efﬂux with extracellular potassium. We ﬁnd that blocking
potassium efﬂux results in rapid dephosphorylation of Syk in par-
allel with inhibition of downstream inﬂammasome signaling. Our
results suggest that Syk is downstream of, and dispensable for,
potassium efﬂux. We hypothesize that potassium efﬂux may pro-
mote Syk activation. Further experiments using site mutagenesis of
Syk phosphorylation sites may be helpful in revealing the details of
this relationship.
The ﬁnding that OXSI-2 inhibits inﬂammasome assembly, pro-
J.R. Yaron et al. / Biochemical and Biophysical Research Communications 472 (2016) 545e550550inﬂammatory cytokine secretion and pyroptotic cell death is
promising for modulating innate immune system-driven inﬂam-
matory processes. Indeed, there are numerous Syk inhibitors
currently in clinical and pre-clinical trials for treating inﬂammatory
and autoimmune pathologies [38e41]. The novel ﬁnding that po-
tassium blockade affects Syk phosphorylation may point to a new
avenue for modulating Syk-dependent inﬂammatory pathologies
by targeting channels and processes that regulate ion homeostasis.
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